首页 > 市场调查报告书 > 製药

动物用医药

市场调查报告书

商品编码

1447815

全球伴侣动物药物市场规模、份额、成长分析，按药物（抗生素、抗发炎药物）、按动物（狗、猫）分类 - 产业预测 2024-2031

Global Companion Animal Drugs Market Size, Share, Growth Analysis, By Medicine(Antibiotics, Anti-inflammatory Drugs), By Animal(Dogs, Cats) - Industry Forecast 2024-2031

出版日期: 2024年02月28日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球伴侣动物药物市场规模为139.9亿美元，预计将从2023年的149.4亿美元成长到2031年的252.9亿美元，预测期间（2024-2031年）复合CAGR为6.8%。

受全球宠物家庭数量不断增加、宠物保健意识增强以及兽药进步等因素推动，全球伴侣动物药品市场大幅成长。宠物数量的增加导致对狗、猫等伴侣动物的药物和治疗的需求激增。推动这一成长的重要因素包括更加重视预防保健，例如疫苗接种和寄生虫控制，以及扩大慢性病的治疗选择范围。此外，市场见证了药物传递方法和配方的创新，例如调味片剂和局部治疗剂，使宠物主人的给药变得更容易。随着宠物主人继续优先考虑他们心爱的动物的健康和福祉，伴侣动物药物市场预计将继续呈上升趋势。这为製药公司和兽医提供了满足这一不断增长和繁荣的市场需求的机会。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Zoetis Inc. (USA)
Elanco Animal Health Inc. (USA)
Merck & Co., Inc. (USA)
Boehringer Ingelheim (Germany)
Bayer AG (Germany)
Virbac (France)
Ceva Sante Animale (France)
Vetoquinol SA (France)
Nexvet (USA)
IDEXX Laboratories, Inc. (USA)
Biogenesis Bago (Argentina)
Nutramax Laboratories, Inc. (USA)
Heska Corporation (USA)
Merial (Sanofi) (France)
Animalcare Group PLC (United Kingdom)
Kindred Biosciences (USA)
Norbrook Laboratories (Ireland)
Kyoritsu Seiyaku Corporation (Japan)
TVM Laboratories (France)
Dechra Pharmaceuticals PLC (United Kingdom)

简介目录

Product Code: SQMIG35I2251

Global Companion Animal Drugs Market size was valued at USD 13.99 Billion in 2022 and is poised to grow from USD 14.94 Billion in 2023 to USD 25.29 Billion by 2031, at a CAGR of 6.8% during the forecast period (2024-2031).

The global market for companion animal drugs has seen substantial growth, driven by factors such as the increasing number of households with pets worldwide, heightened awareness of pet healthcare, and advancements in veterinary pharmaceuticals. The rise in pet ownership has led to a surge in demand for medications and treatments for companion animals, including dogs, cats, and others. Important factors propelling this growth include a greater emphasis on preventive care, such as vaccinations and parasite control, as well as an expanding range of therapeutic options for chronic conditions. Moreover, the market has witnessed innovations in drug delivery methods and formulations, such as flavoured tablets and topical treatments, making administration easier for pet owners. As pet owners continue to prioritize the health and well-being of their beloved animals, the companion animal drugs market is anticipated to continue its upward trend. This presents opportunities for pharmaceutical companies and veterinarians to meet the needs of this growing and flourishing segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Animal Drugs and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Companion Animal Drugs Market Segmental Analysis

The global companion animal drugs market can be segmented into several categories based on factors such as drug, animal, and region. Drug types include antibiotics, anti-inflammatory drugs, parasiticides, and others, while animal types encompass dogs, cats, and others. Geographically, the market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Drivers of the Global Companion Animal Drugs Market

The companion animal drugs market is experiencing growth driven by advancements in veterinary medicine, including the development of improved diagnostics, treatments, and pharmaceuticals. These advancements have led to a broader range of treatment options and better disease management, increasing the demand for advanced companion animal medications.

The market for companion animal drugs is rapidly expanding due to shifting global preferences towards pet ownership. More individuals are adopting dogs and cats, leading to a heightened focus on pet healthcare and pharmaceuticals. This trend has resulted in increased financial investment in improving pet health. Owners, deeply connected to their pets, prioritize their well-being and are willing to invest in companion animal drugs.

Restraints in the Global Companion Animal Drugs Market

The companion animal drugs market is facing a significant challenge in the form of financial burdens associated with these medications and treatments. The high costs may discourage consumers from investing in pet health, potentially delaying or hindering market adoption. Pet owners, particularly those in low-income areas or with limited budgets, may find the expenses of these costly healthcare options for their animals to be prohibitive.

Regulatory bodies tightly control the companion animal drugs market. Compliance with strict rules and obtaining approvals for production and distribution can pose challenges for market players. These stringent requirements can consume a significant amount of time, resulting in a lengthy and expensive process overall. The demanding task of securing approvals and maintaining compliance during development can be arduous, potentially limiting new product entries and causing delays in innovation, which could have negative impacts on the market.

Market Trends of the Global Companion Animal Drugs Market

Digital Health Innovations: The field of veterinary medicine is undergoing changes with the adoption of data analytics and other digital technologies. Wearable devices, telehealth services, and mobile apps have become integrated into veterinary care. These advancements enable pet owners to remotely monitor their pets' health indicators and facilitate communication with consulting veterinarians. Additionally, these technologies aid in managing medication prescriptions with precision.

Emergence of Specialty and Personalized Medications: The companion animal drug market has undergone a significant shift as pet owners increasingly seek personalized and advanced medications for their cats and dogs. Pharmaceutical companies and veterinarians are adapting to this trend by tailoring treatments to suit the diverse health conditions of various animal breeds and sizes. Customized medications are viewed as a potential solution for more effective and precise therapies, with accessibility growing to meet the rising demand.

Focus on Preventive Care: Another notable trend influencing the pet drug industry is the increased emphasis on preventive care for pets. In response to this trend, market players are emphasizing the development and promotion of various products, including wellness and parasite control products, as well as advanced vaccines. Pet owners are prioritizing the health and overall well-being of their pets, leading to a growing demand for preventive medicines.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Companion Animal Drugs Market by Medicine

Market Overview
Antibiotics
Anti-inflammatory Drugs
Parasiticides
and others

Global Companion Animal Drugs Market by Animal

Market Overview
Dogs
Cats
and others

Global Companion Animal Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Zoetis Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Elanco Animal Health Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virbac (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ceva Sante Animale (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vetoquinol S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nexvet (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IDEXX Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogenesis Bago (Argentina)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nutramax Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heska Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merial (Sanofi) (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Animalcare Group PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kindred Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Norbrook Laboratories (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyoritsu Seiyaku Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TVM Laboratories (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dechra Pharmaceuticals PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments